Current Report Filing (8-k)
March 23 2023 - 8:01AM
Edgar (US Regulatory)
0001857044
false
0001857044
2023-03-22
2023-03-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) March 22, 2023
INDAPTUS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40652 |
|
86-3158720 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
3
Columbus Circle 15th Floor |
|
|
New
York |
|
10019 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(646)
427-2727
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
(17
CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
INDP |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On
February 14, 2023, Indaptus Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”)
to report the appointment of Robert Martell, M.D., Ph.D. as a member of the Company’s board of directors (the “Board”)
and a Class I director. At the time of the Initial 8-K, the Board had not determined the committees on which Dr. Martell would serve,
if any. On March 22, 2023, the Board appointed Dr. Martell to serve on the Science and Technology Committee of the Board, effective immediately.
The foregoing information in this Item 5.02 is being filed to amend and supplement the disclosure included in the Initial 8-K.
On
March 22, 2023, the Board appointed Walt A. Linscott, the Company’s Chief Business Officer, as the Company’s Chief Operating
Officer, effective immediately.
Mr.
Linscott’s biographical information is disclosed in Item 10 “Directors and Executive Officers” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 17, 2023
and is incorporated herein by reference.
On
March 22, 2023, the Board set the date of the Company’s 2023 annual meeting of stockholders (the “2023 Annual Meeting”)
as May 25, 2023.
Any
stockholder seeking to bring business before the 2023 Annual Meeting or to nominate a director for election at the 2023 Annual Meeting
pursuant to the Company’s Amended and Restated Bylaws (the “Bylaws”) must provide timely notice, as set forth in the
Bylaws. Specifically, written notice of any proposed business or nomination must be received at the Company’s principal executive
offices at 3 Columbus Circle, 15th Floor, New York, NY 10019 no later than April 2, 2023. Stockholders are advised
to review the Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.
In
addition to satisfying the foregoing requirements under the Bylaws, to comply with the universal proxy rules, stockholders who intend
to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information
required by Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) by April 2, 2023.
Stockholders
who intend to have a proposal considered for inclusion in the Company’s 2023 proxy materials for presentation at its 2023 Annual
Meeting pursuant to Rule 14a-8 under the Exchange Act must submit the proposal in writing to the Company’s Corporate Secretary
by April 2, 2023.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INDAPTUS
THERAPEUTICS, INC. |
|
|
|
Date:
March 23, 2023 |
By: |
/s/
Nir Sassi |
|
Name:
|
Nir
Sassi |
|
Title: |
Chief
Financial Officer |
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024